Last reviewed · How we verify

Creatine monohydrate

Massachusetts General Hospital · FDA-approved active Small molecule

Creatine monohydrate increases phosphocreatine stores in muscle and brain cells, enhancing ATP regeneration and energy availability during high-intensity activity.

Creatine monohydrate increases phosphocreatine stores in muscle and brain cells, enhancing ATP regeneration and energy availability during high-intensity activity. Used for Enhancement of muscle strength and power in high-intensity exercise, Potential adjunctive therapy in neurodegenerative diseases (e.g., Parkinson's disease, ALS), Muscle wasting and weakness in various conditions.

At a glance

Generic nameCreatine monohydrate
Also known ascreatine, crea-pure, creapure, Creapure, HD-02, Creapure, AlzChem AG, Trostberg, Germany
SponsorMassachusetts General Hospital
Drug classNutritional supplement / Ergogenic aid
TargetCreatine kinase system; phosphocreatine shuttle
ModalitySmall molecule
Therapeutic areaSports performance, Neurology, Muscle disorders
PhaseFDA-approved

Mechanism of action

Creatine is converted to phosphocreatine in cells, where it serves as a rapid ATP buffer system. During intense muscle contraction or neural activity, phosphocreatine donates its phosphate group to ADP, regenerating ATP and sustaining energy production. This mechanism improves performance in short, high-intensity efforts and may support cognitive function and cellular energy metabolism.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: